The Lancet Oncology: March 26, 2008

Editor David Collingridge discusses highlights from the April issue including: encouraging results from the START trials suggest fewer fractions of radiotherapy could revolutionise treatment of early stage breast cancer; how a phase II study investigating yttrium-90 labelled ibritumomab could have an important future role in the treatment of follicular non-Hodgkin lymphoma, and finally the pressing need for increased recruitment of adolescents and young adults in to cancer trials. Tell us wha...